Catalent reportedly to buy Paragon Bioservices for $1.2 billion
Catalent said on Monday it would buy privately held gene therapy-focused Paragon Bioservices in an all-cash deal for $ 1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments. Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing and manufacturing products such as complex biopharmaceuticals for… Read More »